OncoMatch/Clinical Trials/NCT06449781
177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer
Is NCT06449781 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Lutetium (177Lu) vipivotide tetraxetan for prostate cancer.
Treatment: Lutetium (177Lu) vipivotide tetraxetan — Single-center, non-commercial phase 2 clinical trial to evaluate 177Lu-PSMA as a systemic adjuvant treatment in patients with high and very high risk prostate cancer after radical treatment using locoregional teleradiotherapy and hormone therapy
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: radical locoregional treatment
Completion of radical locoregional treatment
Lab requirements
Blood counts
neutrophils > 1500x10^9/l; thrombocytes > 100,000x10^9/l; hemoglobin > 9 g/dl
Kidney function
egfr > 50 ml/min; albumin >2.5 mg/ml
Liver function
bilirubin < 2xuln (gilbert's syndrome < 5xuln); aminotransferase < 3xuln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06449781 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received radical locoregional treatment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages